Some women who take oestrogen for more than five years seem more likely to develop endometrial cancer. Since 1975 several North American casecontrol studies have reported an association between oestrogen use and endometrial cancer (see Weinstein 1980) , although European studies have failed to find the same association, perhaps due to differences in prescribing practices (Lauritzen et al. 1978 , Salmi 1980 . In recent studies with improved sampling procedures and adjustment for the bias which is inherent in casecontrol methods, the risk of endometrial cancer is three to four times higher for oestrogen users. A causal connection is implied in these studies which find a higher risk with increasing dosage and longer duration of oestrogen use (Jelovsek et al. 1980 , Shapiro et al. 1980 . The case for a causal connection is further strengthened by the rise in incidence of endometrial cancer in the United States before 1975; as oestrogen use declined after 1975, the frequency of endometrial cancer among American women in the sixth decade then fell, while rates for older women who are less likely to use oestrogen have continued to rise (Walker & Jick 1979 . Although the case for a link between oestrogen and endometrial cancer is not proven, the association cannot be simply attributed to the failures of case-control methodology when similar findings appear in multiple studies with a wide variety of control populations.
It seems clear now that oestrogen is associated with a particularly mild form of endometrial cancer. Oestrogen use is associated with favourable tumour characteristics including earlier stage, lower grade, and fewer instances of myometrial invasion (Mack et al. 1976 , McDonald et al. 1977 , Miller et al. 1978 , Antunes et al. 1979 . Superior survival is reported in women who have been exposed to oestrogen and later developed endometrial cancer (Miller et al. 1978 , Schindler 1976 , McDonald et al. 1977 . In a recent study of 860 Ontario women with endometrial cancer, 259 women who gave a history of oestrogen use for six months or more at some time before diagnosis experienced a five-year survival of 92 + 2% compared with 68 + 2% for non-users. When the data were adjusted for the presence of favourable prognostic factors among the oestrogen users, there remained a 5.4 times greater risk of death from endometrial cancer for non-users (Collins et al. 1980) . A superior survival for women who were oestrogen users is compatible with the continuing decrease in endometrial cancer mortality during the period when increased incidence was observed (Greenwald et al. 1977 , Cancer in Ontario 1977 . The association between prior oestrogen use and superior survival with endometrial cancer may have several explanations: oestrogen use may occur in women who have better health; oestrogen use may lead to an earlier diagnosis of endometrial cancer; tumours associated with oestrogen use may include borderline hyperplasias which are not malignant; and tumours associated with prior oestrogen use may have less aggressive characteristics than those which develop in the absence of oestrogen. The following discussion examines the extent of the effect of these health and diagnostic differences on endometrial cancer survival, and describes a sequence of events -in which the action of oestrogen may be specific to the development of less aggressive endometrial cancer.
If oestrogen use is a marker for better health, then endometrial cancer patients who are oestrogen users will be more likely to survive as there will be fewer deaths during the treatment of the disease and fewer non-cancer deaths during the period of follow up. There is some evidence to suggest that oestrogen users, who are generally in a higher socioeconomic class and report more years of formal education than non-users, may enjoy superior health (Stadel & Weiss 1975) . For example, oestrogen users in a southern United States private gynaecological practice experienced low rates of cancers in general and a lower ageadjusted mortality than expected from United States population data (Burch et al. 1974) . There is also evidence that oestrogen users experience fewer non-cancer deaths during the period of follow up after diagnosis of endometrial cancer. When all deaths, including non-cancer deaths, were examined in the Ontario study, the adjusted summary odds ratio was 2.7 (X2 6.7; P <0.01), implying a greater risk of death from all causes for non-users of oestrogen. The relative risk (not adjusted for favourable tumour characteristics) of experiencing a non-cancer death was 2.3 (twotailed 95% confidence limits 1.9, 2.8). Although oestrogen users have fewer non-cancer deaths than non-users, the better health of oestrogen users does not account for the 5.4 times higher death rate from endometrial cancer experienced by nonusers of oestrogen (Collins et al. 1980 ).
Oestrogen use may also lead to earlier diagnosis of women with endometrial cancer, and thus a greater likelihood of survival for women who receive their treatment before the disease has extended. It is suggested that earlier diagnosis is more likely because oestrogen users attend physicians more often. Indeed the higher socioeconomic class and education of oestrogen users ensures greater exposure to physicians for routine and other health measures (Weiss 1978) . However, in case-control studies an earlier age at diagnosis for oestrogen users is not consistently observed, and in survival studies oestrogen users with late stages of endometrial cancer also experience superior survival (Jelovsek et al. 1980 , Collins et al. 1980 . Although early treatment may diminish deaths in endometrial cancer, the effect of early diagnosis on survival has not been estimated and does not seem to be sufficient to account for the better prognosis for oestrogen users.
The association between oestrogen and endometrial cancer in case-control studies and the superior resulting survival of oestrogen users have been attributed to uncertainties in the diagnosis of borderline endometrial tumours. Oestrogen induces endometrial hyperplasia which is not easily distinguished from endometrial cancer (Novak & Woodruff 1974) . When hyperplastic endometrium is wrongly classified as endometrial cancer, a spurious association of endometrial cancer with oestrogen use occurs and the patients with misclassified endometrial cancer may be expected to have superior survival. If pathologists extend the margin of safety toward the benign end of the spectrum, the term endometrial cancer is gradually extended to include lesions which may spontaneously regress, a behaviour which does not agree with our understanding of the biological nature of cancer. This tendency to lower the standards for the diagnosis of endometrial cancer is invoked to explain the increase in incidence in endometrial cancer in Malta and Czechoslovakia, where oestrogen use is rare (Rosol et al. 1976 , Sultana & Camilleri 1977 . However, there is some evidence that the caution of pathologists is not the reason for the association between oestrogen and endometrial cancer, nor for the apparently mild resulting cancers. When tissues from cases in studies of oestrogen use have been re-examined by pathologists, there is generally agreement that 75-90% of the tumours are endometrial cancers (Gordon et al. 1977 , Collins et al. 1980 ). Gordon et al. (1977) found further that the frequency of oestrogen use was highest in their 'unanimous concurrence' group of patients, that is in those patients in whom all pathologists agreed on the diagnosis. As tumours linked with oestrogen use were uniformly classed as endometrial cancer by creditable gynaecological pathologists, it is unreasonable to attribute the association between oestrogen and superior survival to a tendency to diagnose non-malignanr oestrogen-induced hyperplasias as cancer.
If the association of oestrogen use with superior survival in endometrial cancer cannot be ascribed to the better health and earlier diagnosis of disease in oestrogen users, nor to the pathologic misclassifications of oestrogen-induced benign hyperplasia, then it is important to consider the additional possibility that oestrogen is associated with a less aggressive tumour. The connection is plausible if oestrogen enhances the sequence of cellular events which precede cancer, and if oestrogenic action favours cells which are destined to become well-differentiated tumours. Current views on the intracellular actions of oestradiol, the metabolism of pharmacologic oestrogens and chemical carcinogenesis are compatible with an action of oestrogen which is specific to the development of well-differentiated tumours.
Carcinogenesis is understood to be a continuous sequence of cancer development which may be subdivided into four stages: initiation, promotion, neoplastic development and, finally, the clinical manifestations of tumour. The neoplasm probably originates in a single cell, through the induction of a biochemical neoplastic change which is irreversible and mutation-like (Fialkow 1972) . A variety of stimuli may cause initiation, including radiation, viral infection and chemical exposure. When the stimulus causing the initial biochemical change is chemical, the exposure to the chemical may be brief, and the chemical need not be present thereafter (Farber & Cameron 1980) . The first step in carcinogenesis must be followed by sufficient cell replication to ensure the propagation of the initiated cells to a level of independent growth. Among the chemicals known to initiate tumours is a group of polycyclic aromatic hydrocarbons including dibenzanthracene and benzopyrene. The specific chemical structures that lead to initiation of cancer development in polycyclic aromatic hydrocarbon carcinogens are not known, but their carcinogenic activity is generally associated with unsaturated or aromatic inner rings (Hoffman et al. 1978 , Arcos & Argus 1974 . Although oestradiol is a polycyclic hydrocarbon with a single aromatic ring, oestradiol and the products of its metabolism are not characterized by aromatic inner rings. No known pharmacologic oestrogen products resemble the aromatic hydrocarbon carcinogens, although two minor conjugated oestrogens (equilen and equilenin) have one and two double bonds respectively in the B ring (Herr et al. 1970) . The possibility that oestradiol or oestrogen-like compounds may be involved in the initiation of endometrial cancer cannot be excluded on grounds of chemical structure, but is diminished by current knowledge of structural correlations with carcinogenicity. Further, the short latency period (3-6 years) for oestrogen-linked tumours is not consistent with the long period required for chemical initiation of malignant change .
There is evidence, however, that oestradiol may be a promoting agent which stimulates a series of cell replications, thereby allowing the initiated cell to reach independent growth in the sequence of neoplastic development. Endometrium which has been exposed to oestrogen accumulates nucleic acids in preparation for DNA synthesis, mitosis and proliferation of glandular epithelial cells (Stormshak et al. 1978) . For cell proliferation to occur in response to oestradiol, the cell regulatory mechanisms which incorporate oestradiol should be functional. The sequence of events by which oestradiol enters cells, binds to an intracellular protein receptor, and through a process requiring energy is translocated into the nucleus has been reviewed in this journal (Jacobs 1979) . The presence and integrity of receptor proteins is essential to the short-term (up to 4-6 hours) and long-term nuclear retention of oestradiol. In the immature rat uterus, long-term nuclear retention is required for true uterine growth, and uterine cells may contain as many as 20 000 receptor sites, of which one-tenth are translocated to the nucleus in the presence of physiological quantities of oestradiol (Clark et al. 1978) . It is not the initial entry of oestradiol into the nucleus, but a sustained presence in the nucleus that elicits maximal DNA synthesis and mitosis in preparation for cell division and growth (Stormshak et al. 1978) . This series of events requires intact cell regulatory mechanisms to ensure the prolonged presence of oestradiolreceptor complex in the nucleus. The specific requirements for this late action of oestradiol may not be found in undifferentiated tumour cells where cytosol receptors for oestradiol may be less plentiful (McCarty et al. 1979) . Oestradiol may then be expected to play a selective role in the promotion of clones of initiated cells which show the least deviation from normal -conditions which are likely to lead specifically to the development of well-differentiated adenocarcinomas of the endometrium.
The following sequence in association with the effect of oestrogen in the endometrium then seems plausible: endometrial cells undergo a random' biochemical event and become initiated cancer cells; the administration of oestrogen leads to cell proliferation in the endometrium; when the administration of oestrogen coincides with the presence of initiated tumour cells, there is a higher probability of promoting those tumour cells to the stage of malignant neoplasia; oestrogen selectively promotes those cells which have intact regulatory mechanisms including oestradiol receptors; and therefore oestrogen use is associated with tumours which are well-differentiated. The association of endometrial cancer with oestrogen use does not become apparent before three to five years of exposure, implying that the initiating event is rare and/or the period of cell proliferation required is long. When oestradiol is withdrawn, the risk of endometrial cancer diminishes, implying that the initiating event may be dependent on subsequent exposure to oestrogen for its development to clinical cancer. What cannot be determined at this time is whether cell proliferation promotes the propagation of initiated cells, or whether the cell proliferation leads to an environment in which initiation is itself more likely. From the results of studies done to date, one cannot distinguish between an origin of cancer from a single original normal cell or from a single cell at any later step in the sequence (Farber & Cameron 1980) .
As the number of females in the sixth and seventh decade increases, menopausal symptoms will be more frequently encountered, and there may be an increasing demand for therapy to prevent osteoporosis. If a role for oestrogen in the prevention of osteoporosis is defined, then a thorough understanding of the risk of oestrogen use is mandatory. No drug is free of side effects, but death due to endometrial cancer associated with oestrogen use should be avoidable if reasonable care is taken in prescribing habits and follow up.
When prescribing oestrogen, the lowest dose and the shortest duration of the drug which will achieve the desired effect should be used. Occasional, if not monthly use of progesterone derivatives is advised, although it remains unclear whether progesterone prevents the development of endometrial abnormalities (Nachtigall et al. 1979 , Rosenwaks et al. 1979 , Thom & Studd 1980 . The logic of progesterone use is compelling on several grounds. Progesterone reduces the number of oestradiol cytosol receptors. Progesterone also induces the activity of 17fl-hydroxy steroid dehydrogenase, thereby increasing the conversion of oestradiol to oestrone (Tseng 1979) . Results of perfusion experiments in human proliferative endometrium suggest that oestrone does not bind to the nuclear receptor (Tseng & Gurpide 1973 , Gurpide 1978 . Finally, progesterone given for a period of ten days or more in a sufficiently high dosage will generally cause the endometrium to slough.
Careful follow up to detect abnormal uterine bleeding is essential. For several reasons there does not appear to be sufficient indication to perform regular screening procedures in women without symptoms: uterine bleeding occurs in the majority of women with endometrial cancer, and in virtually all women receiving oestrogen who develop endometrial cancer (Horwitz & Feinstein 1978) ; the cancers occurring in oestrogen users are early and/or less aggressive , Collins et al. 1980 ; and the only efficient screening method appears to be endometrial biopsy (Ferenczy et al. 1978) . Endometrial biopsy is a painful procedure and few women will permit its repetition for screening purposes. Imposing regular endometrial biopsies on oestrogen users would also remove the care of postmenopausal women from family doctors, who may have wider knowledge of, their needs than specialists. In the absence of an acceptable screening procedure some agreement on a definition of abnormal uterine bleeding is needed, as bleeding may occur frequently in the intervals between hormone cycles. Bleeding at any other time is abnormal and requires removal of the endometrium by biopsy or curettage whenever it occurs.
The new information on oestrogen that has accumulated in the last five years has suggested that the risk of oestrogen therapy has been overstated. It would seem on the evidence now available that an understanding of oestrogen action and adherence to pharmacological principles in its use may permit the elimination of any significant risk to the endometrium.
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